ResMed (RMD) PT Raised to $300 at RBC Capital

RBC Capital analyst Craig Wong-Pan raised the price target on ResMed (NYSE: RMD) to $300.00 (from $294.00) while maintaining an Outperform rating.

The analyst commented: "Consensus beats across all key line items, strong outlook for gross margins; RMD delivered a strong 4Q25 result which beat consensus expectations across all key line items and management provided FY26 gross margin guidance well ahead of RBCe and consensus estimates. The one detractor was Americas devices (with growth marginally below expectations), however we do not consider this a significant issue given the company continued to deliver solid growth of 7% YoY. We have revised our forecasts which has lifted our PT to $300/share (from $294) and we maintain an OP rating."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Mosaic sets pricing for tender offers on up to $1.4B in debt